Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED.

CHAARTED was an ECOG-led phase III trial looking at early chemotherapy with the use of docetaxel in addition to androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer.

The positive results of the trial showing marked improvement in overall survival in those who received chemotherapy with ADT have revolutionized the treatment of metastatic castration-sensitive prostate cancer. In addition to overall survival, secondary endpoints such as time to castration resistance, PSA response were also significant for the patients who received early chemotherapy.

Asian journal of andrology. 2015 Oct 27 [Epub ahead of print]

Jeanny B Aragon-Ching

Clinical Program Director of Genitourinary Cancers, INOVA Dwight and Martha Schar Cancer Institute, 8505 Arlington Boulevard, Suite 100, Fairfax, VA, USA.